Arcutis Biotherapeutics, Inc.ARQTNASDAQ
Loading
ARQT Revenue Growth (YoY Quarterly)•+81.48%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+81.48%
-40.2pp
+82.79%
-47.9pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+6.03%
+3.4pp
+12.13%
+5.2pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +427.58% | +32.84% | +164.13% | +121.69% | +81.48% |
| Gross Profit Growth | +471.41% | +23.11% | +170.18% | +130.65% | +82.79% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +30.65% | +13.50% | +2.85% | +2.67% | +6.03% |
| Weighted Average Shares Diluted Growth | +30.65% | +13.50% | +2.85% | +6.90% | +12.13% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +183.12% | +129.89% | +145.76% | +91.48% | +100.13% |
| Inventory Growth | +10.60% | +25.42% | +17.61% | +59.96% | +55.82% |
| Asset Growth | +2.20% | -28.09% | -20.76% | -15.18% | +24.10% |
| Book Value per Share Growth | +35.99% | -44.12% | -27.52% | -1.71% | +13.43% |
| Debt Growth | -46.30% | -46.41% | -46.93% | -45.35% | -94.33% |
| R&D Expense Growth | -39.10% | -24.19% | +0.80% | +0.53% | +41.24% |
| SG&A Expenses Growth | +18.35% | +16.80% | +18.90% | +6.10% | +37.10% |
1 / 4